Loading clinical trials...

Development and Validation of a Comorbidity Index in Crohn's Disease | Clinical Trials | Clareo Health

COMPLETED

Development and Validation of a Comorbidity Index in Crohn's Disease

NCT05253378•Central Hospital, Nancy, France

Summary

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD). Like other chronic diseases, patients with CD may be affected by other diseases called comorbidities. The prevalence of comorbidities in IBD patients ranges from 30 to 70 %. Unlike other chronic diseases, there is currently no CD-specific tool to assess the impact of comorbidities on patients' lives in order to take appropriate medical measures. Several clinical indexes have been developed for the study of comorbidities, including the Charlson index and the Groll index, which are widely used. The disadvantage of these indexes is that they are not adapted to patients with CD. The primary objective of this study is to develop and validate a clinical index to evaluate the impact of comorbidities on disability in patients with CD.

Eligibility

Age

18 - 59 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients between 18 and 59 years old
•2. Established diagnosis of CD with a minimum disease duration of 3 months
•3. Disease considered by the treating gastroenterologist to have been stable for at least 3 months

Exclusion Criteria

•1. Subject unable to comply with study procedures
•2. Surgery for CD 3 months prior to inclusion visit

Locations (2)

Laurent PEYRIN-BIROULET

Vandœuvre-lès-Nancy, France

San Raffaele Hospital

Milan, Italy

Key Dates

Start Date

April 4, 2022

Primary Completion Date

March 31, 2025

Completion Date

March 31, 2025

Last Updated

May 6, 2025

Enrollment

458

ACTUAL participants

Conditions

Crohn Disease

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Development and Validation of a Comorbidity Index in Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study